Versant 2.0 HCV assay launched in Europe
Bayer Healthcare, a division of Germany's Bayer group, and Belgian firm Innogenetics NV, have announced the European launch of their co-developed Versant HCV (Hepatitis C virus) Genotype 2.0 assay. The firms added that the product, which was developed using Innogenetics IP and is an updated version of Bayer's market-leading type 1.0 assay, will play a key role in genotypic identification of infection.
The companies explained that the assay is able to accurately classify HCV genotypes 1 to 6 as well as subtypes 6c-l (formerly known as 7, 8 and 9). Such accuracy is necessary, say the firms, because each strain of the virus responds differently to treatment.
Frank Morich, Innogenetics' chief executive, said: "Bayer's decision to develop an updated version [of the assay], based on our LiPA platform, is a further validation of our technology and know-how."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze